Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial

Jun Sik Yoon, Won Sohn, Oh Young Lee, Sang Pyo Lee, Kang Nyeong Lee, Dae Won Jung, Hang Lak Lee, Byung Chul Yoon, Ho Soon Choi, Won Seok Chung, Jae Gu Seo

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background and Aim: The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated. Methods: This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multispecies probiotics (a mixture of Bifidobacterium longum, B.bifidum, B.lactis, Lactobacillus acidophilus, L.rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a day for 4 weeks. The primary efficacy end-point was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary end-points were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays. Results: The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) versus 37.5% (9/24) (P<0.05). Secondary end-points such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B.lactis, L.rhamnosus, and S.thermophilus had increased significantly in the probiotics group after 4 weeks and that B.lactis had increased in the placebo group. Conclusions: Multispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota.

Original languageEnglish
Pages (from-to)52-59
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume29
Issue number1
DOIs
StatePublished - 2014 Jan 1

Fingerprint

Irritable Bowel Syndrome
Probiotics
Placebos
Abdominal Pain
Streptococcus thermophilus
Lactobacillus acidophilus
Real-Time Polymerase Chain Reaction

Keywords

  • Irritable bowel syndrome
  • Microbiota
  • Probiotics

Cite this

@article{8be7ca25a97448919c04c1d35d7c0497,
title = "Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial",
abstract = "Background and Aim: The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated. Methods: This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multispecies probiotics (a mixture of Bifidobacterium longum, B.bifidum, B.lactis, Lactobacillus acidophilus, L.rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a day for 4 weeks. The primary efficacy end-point was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary end-points were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays. Results: The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0{\%} (17/25) versus 37.5{\%} (9/24) (P<0.05). Secondary end-points such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B.lactis, L.rhamnosus, and S.thermophilus had increased significantly in the probiotics group after 4 weeks and that B.lactis had increased in the placebo group. Conclusions: Multispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota.",
keywords = "Irritable bowel syndrome, Microbiota, Probiotics",
author = "Yoon, {Jun Sik} and Won Sohn and Lee, {Oh Young} and Lee, {Sang Pyo} and Lee, {Kang Nyeong} and Jung, {Dae Won} and Lee, {Hang Lak} and Yoon, {Byung Chul} and Choi, {Ho Soon} and Chung, {Won Seok} and Seo, {Jae Gu}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/jgh.12322",
language = "English",
volume = "29",
pages = "52--59",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
number = "1",

}

TY - JOUR

T1 - Effect of multispecies probiotics on irritable bowel syndrome

T2 - A randomized, double-blind, placebo-controlled trial

AU - Yoon, Jun Sik

AU - Sohn, Won

AU - Lee, Oh Young

AU - Lee, Sang Pyo

AU - Lee, Kang Nyeong

AU - Jung, Dae Won

AU - Lee, Hang Lak

AU - Yoon, Byung Chul

AU - Choi, Ho Soon

AU - Chung, Won Seok

AU - Seo, Jae Gu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background and Aim: The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated. Methods: This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multispecies probiotics (a mixture of Bifidobacterium longum, B.bifidum, B.lactis, Lactobacillus acidophilus, L.rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a day for 4 weeks. The primary efficacy end-point was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary end-points were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays. Results: The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) versus 37.5% (9/24) (P<0.05). Secondary end-points such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B.lactis, L.rhamnosus, and S.thermophilus had increased significantly in the probiotics group after 4 weeks and that B.lactis had increased in the placebo group. Conclusions: Multispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota.

AB - Background and Aim: The efficacy of treatment with multispecies probiotics on irritable bowel syndrome (IBS) symptoms and the alterations of gut microbiota in patients who have taken probiotics were investigated. Methods: This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multispecies probiotics (a mixture of Bifidobacterium longum, B.bifidum, B.lactis, Lactobacillus acidophilus, L.rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks or to receive a placebo twice a day for 4 weeks. The primary efficacy end-point was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary end-points were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the 4 weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time polymerase chain reaction assays. Results: The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) versus 37.5% (9/24) (P<0.05). Secondary end-points such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B.lactis, L.rhamnosus, and S.thermophilus had increased significantly in the probiotics group after 4 weeks and that B.lactis had increased in the placebo group. Conclusions: Multispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota.

KW - Irritable bowel syndrome

KW - Microbiota

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=84897584406&partnerID=8YFLogxK

U2 - 10.1111/jgh.12322

DO - 10.1111/jgh.12322

M3 - Article

C2 - 23829297

AN - SCOPUS:84897584406

VL - 29

SP - 52

EP - 59

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 1

ER -